ABSTRACT
Objective: To investigate the neuroprotective effects of Shunaoxin Dropping Pill (SDP) on Alzheimer's disease (AD) rats induced by D-galactose their mechanisms. Methods: Rats were ip given D-gal (100 mg/kg) for 60 d to induce the prominent changes of AD in the early stage. Morris water maze was used to investigate neurobehavioral changes, superoxide dismutase (SOD) and malondialdehyde (MDA) kits were used to determine the indicators of oxidative stress, immunohistochemistry was used to evaluate the expression of GFAP and Caspase-3, and HE staining was used to observe the morphological changes in hippocampal region. Results: SDP treated group significantly decreased latency and increased the bouts of cross platform in Morris water maze experiment (P < 0.05), improved the morphological changes in hippocampal region and significantly increased the content of SOD content (P < 0.05), decreased the content of MDA (P < 0.05), and alleviated the neuron death. Conclusion: SDP has the certain therapeutic effect on prominent changes of AD in the early stage through its anti-oxidant stress effect. Our study provides the first piece of evidence supporting the potential use of SDP in the treatment of AD in clinic.
ABSTRACT
Objective: To evaluate the effect of Shunaoxin Dropping Pill (SDP) on blood pressure and cardiac protection in spontaneously hypertensive rats (SHRs). Methods: The SHRs were randomly divided into three groups, model (M) group, SDP group, and valsartan (VL) group. Non-invasive blood pressure instrument was used to measure blood pressure. Serum content of nitric oxide synthase (NOS) and angiotensin II (Ang II) were measured using kits for 6 weeks after ig administration. Doppler echocardiography was used to evaluate left ventricular weight, and HE staining was used to assess aortic and cardiac morphology. Results: The blood pressure of SHRs decreased to minimum 1 h after ig administration of SDP (800 mg/kg). Long-term use of SDP could stabilize blood pressure of SHRs. Serum content of NOS in SDP group was significantly more than that in M group (P < 0.05). The serum content of Ang II in SDP group was significantly less than that in M group (P < 0.05). The left ventricular weight of SDP group was significantly lower than that in M group (P < 0.05). SDP administered group can improve myocardial and aortic morphology abnormalities caused by hypertension. Conclusion: SDP has a certain therapeutic effect on hypertensive with myocardial hypertrophy rats, it can be used as a potential drug on hypertensive disorders associated with cardiac hypertrophy.
ABSTRACT
Objective: To study the anticoagulant effect of Shunaoxin Dropping Pill (SDP) alone or in combination with Warfarin sodium on platelet aggregation and provide the experimental support for the clinical safety of medication. Methods: Experiments were carried out in control group, low-dose SDP group, high-dose SDP group (45.36 and 90.72 mg/kg), and Warfarin sodium (clinical equivalent dose 0.4 mg/kg) group, Combined administration with low-dose SDP and high-dose SDP groups+clinical equivalent dose of Warfarin sodium. We determined the platelet aggregation rate of rats in the control group, low-dose SDP group, and high-dose SDP group in vitro by turbidimetry. We made iac administration of SDP and Warfarin sodium for 3 d, and took abdominal aortic blood for separating the platelets and used nephelometry for determining platelet aggregation rate; We separated serum and used semi-automatic coagulation analyzer to test APTT, PT, and TT. Results: Compared with the control group, SDP had the strong anti-platelet aggregation in vitro and could inhibit the increase of platelet aggregation in vivo slightly with the dose increasing. SDP could prolong APTT, PT, and PT; Compared with the single drug group, the combination therapy had no obvious effect on the platelet aggregation but could significantly extend the APTT, PT, and TT. Conclusion: SDP has some inhibition on platelet aggregation with anticoagulant effect; Combined with Warfarin sodium, SDP has a synergistic interaction on anticoagulant effect with Warfarin sodium.
ABSTRACT
OBJECTIVE: To establish an LC-MS method for simultaneous determination of six compounds (uridine, guanosine, ferulic acid, ligustilide, senkyunolide I and II in Shunaoxin dropping pills. METHODS: The analysis was performed on a Waters Acquity BEH C18 column (2.1 mm × 100 mm, 1.7 μm) with the mixture of acetonitrile-water-formic acid as the mobile phase, and the flow rate was 0.4 mL · min-1; the PDA detection wavelength was 190-400 nm; the column temperature was room temperature (30°C). RESULTS: The linear ranges for uridine, guanosine, ferulic acid, ligustilide, senkyunolide I and H were 10.31-206.24, 3.28-65.52, 6.36-127.24, 8.24-164.88, 10.18-200.52, and 3.14-62.72 μg · mL-1, respectively. The average recoveries were between 99%-101% (n=6). CONCLUSION: This method is simple, accurate and reliable to determine the contents of the six compounds in Shunaoxin dropping pills for the quality control.